Prognostic factors of early recurrence after complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Table 2 Perioperative details and outcomes

Characteristic	All	< 1 yr group, n = 39	≥ 1 yr group, n = 41	P value
Surgical method
Laparoscopy	11 (13.7)	5 (12.8)	6 (14.6)	1.000
Laparotomy	69 (86.3)	34 (87.2)	35 (86.4)
Preoperative PCI	7.99 ± 5.97	9.08 ± 6.52	6.95 ± 5.26	0.112
CC score
0	63 (78.8)	25 (64.1)	38 (92.7)	0.002a
1	17 (21.2)	14 (35.9)	3 (7.3)
Residual lesion
Small bowel	6 (7.5)	4 (10.3)	2 (4.9)
Large bowel	1 (1.3)	1 (2.6)	0
Major vessels	3 (3.8)	3 (7.7)	0
Peritoneum	7 (8.8)	6 (15.4)	1 (2.4)
Pre-HIPEC chemotherapy1	41 (51.3)	24 (61.5)	17 (41.5)	0.080
Response to pre-HIPEC chemotherapy				0.121
Complete remission	0	0	0
Partial remission	15 (18.8)	8 (20.5)	7 (17.1)
Stable disease	6 (7.5)	1 (2.6)	5 (12.2)
Progression disease	16 (20.0)	11 (28.2)	5 (12.2)
CRS time in min	338.60 ± 144.80	365.50 ± 135.10	313.10 ± 150.80	0.106
Visceral organ resections
Liver	6 (7.5)	3 (7.7)	3 (7.3)	1.000
Lung wedge resection	3 (3.8)	1 (2.6)	2 (4.9)	1.000
Small bowel	23 (28.8)	13 (33.3)	10 (24.4)	0.461
Large bowel	45 (56.3)	25 (64.1)	20 (48.8)	0.184
Uterus and adnexa2
TH-BSO	7 (13.2)	2 (8.3)	5 (17.2)	0.433
BSO	3 (5.6)	1 (4.2)	2 (6.9)	1.000
HIPEC duration in min				0.603
30, oxaliplatin-based	18 (22.4)	10 (25.6)	8 (19.5)
60	31 (38.8)	16 (41.0)	15 (36.6)
90, mitomycin c	31 (38.8)	13 (33.3)	18 (43.9)
HIPEC regimens
Cisplatin-based	22 (27.5)	13 (33.3)	9 (22.0)	0.319
Non-cisplatin-based	58 (72.5)	26 (66.7)	32 (78.0)
Post-HIPEC chemotherapy3	70 (87.5)	35 (89.7)	35 (85.4)	0.738
Any postoperative complication ≥ grade 3	7 (8.8)	4 (10.3)	3 (7.3)	0.709
AKI	1 (1.3)	0	1 (2.4)
Bowel perforation	4 (5.0)	4 (10.3)	0
Others	2 (2.5)	0	2 (4.9)
Recurrent site				< 0.001a
Extraperitoneal	23 (28.8)	18 (46.2)	5 (12.2)
Intraperitoneal	26 (32.5)	9 (23.1)	17 (41.5)
Both	17 (21.3)	12 (30.8)	5 (12.2)
No recurrence	14 (17.5)	0	14 (34.1)

^aP < 0.05.

¹Within 6 mo before hyperthermic intraperitoneal chemotherapy (HIPEC).

²Female only.

³Within 6 mo after HIPEC.

Data are n (%) or mean ± standard deviation. AKI: Acute kidney injury; BSO: Bilateral salpingo-oophorectomy; CC: Completeness of cytoreduction; CRS: Cytoreductive surgery; HIPEC: Hyperthermic intraperitoneal chemotherapy; PCI: Peritoneal cancer index; TH-BSO: Total hysterectomy with bilateral salpingo-oophorectomy.